yourfanat wrote: I am using another tool for Oracle developers - dbForge Studio for Oracle. This IDE has lots of usefull features, among them: oracle designer, code competion and formatter, query builder, debugger, profiler, erxport/import, reports and many others. The latest version supports Oracle 12C. More information here.
Cloud Expo on Google News
Cloud Expo & Virtualization 2009 East
Smarter Business Solutions Through Dynamic Infrastructure
Smarter Insights: How the CIO Becomes a Hero Again
Windows Azure
Why VDI?
Maximizing the Business Value of Virtualization in Enterprise and Cloud Computing Environments
Messaging in the Cloud - Email, SMS and Voice
Freedom OSS
Stairway to the Cloud
Sun's Incubation Platform: Helping Startups Serve the Enterprise
Cloud Computing & Enterprise IT: Cost & Operational Benefits
How and Why is a Flexible IT Infrastructure the Key To the Future?
Click For 2008 West
Event Webcasts
A*STAR Scientists Identify Potential Drug Target for Inflammatory Diseases Including Canvers

This discovery holds the potential to reduce healthcare costs for many common inflammatory diseases such as cancer and diabetes

Singapore, Nov 21, 2012 - (ACN Newswire) - A*STAR scientists have identified the enzyme, telomerase, as a cause of chronic inflammation in human cancers. Chronic inflammation is now recognized as a key underlying cause for the development of many human cancers, autoimmune disorders, neurodegenerative diseases, and metabolic diseases such as diabetes. This enzyme, which is known to be responsible for providing cancer cells the endless ability to divide, is now found to also jumpstart and maintain chronic inflammation in cancers.

In identifying this enzyme, inflammation can be prevented or reduced, and the common ailments can be alleviated. This discovery has considerable impact on healthcare because developing drugs to target telomerase can greatly reduce healthcare costs.

Currently, the annual costs and expenses associated with cancer and metabolic diseases such as diabetes amount to about $132 billion in the US alone(1). Although many safe and effective anti-inflammatory drugs such as aspirin are currently available on the market, these drugs sometimes have side effects because blocking inflammation is typically detrimental to normal physiology. Hence there exists a need for the development of cost-effective drugs that are targeted, so as to minimize side effects.

This collaborative research was conducted by scientists at A*STAR's Institute of Molecular and Cell Biology (IMCB) led by Assoc Prof Vinay Tergaonkar, A*STAR's Genome Institute of Singapore (GIS) and National University of Singapore. Other clinical collaborators include Cancer Science Institute of Singapore and Duke-NUS Graduate Medical School. The research findings were published on Nov. 18, 2012, in the prestigious scientific journal, Nature Cell Biology.

The team identified that telomerase directly regulates the production of inflammatory molecules that are expressed by NF-kB, a known master regulator of chronic inflammation. These molecules are critical for inflammation and cancer progression. By inhibiting telomerase activity in primary cancer cells obtained from patient samples, the scientists found that levels of IL-6, an inflammatory molecule known to be a key driver of human cancers, was reduced in expression as well. This is an important breakthrough that shows how targeting telomerase with drugs could potentially reduce inflammation, and hence get rid of cancer cells.

Dr Tergaonkar said, "These findings provide a unifying explanation for a decade worth of observations from leading laboratories in the field which show that chronic inflammation and telomerase hyperactivity co-exist in over 90 percent of human cancers. What we show that these two activities are actually interdependent. They also may lead to potentially novel drugs that will target a range of human ailments with inflammation as an underlying cause, which range from arthritis to cancer."

Prof Hong Wan Jin, Executive Director of IMCB, said, "The discovery speaks for the exceptional power of identifying novel mechanisms that have translational potential, through close collaborations among scientists in different A*STAR institutes, as well as to bring together both basic and clinical research scientists in Singapore. I am confident that we can expect more discoveries like this from Dr Tergaonkar's team."

(1) National Institute of Diabetes and Digestive and Kidney Diseases

The research findings described in this media release can be found in the 18 November online issue of Nature Cell Biology, under the title, "Telomerase directly regulates NF-kB-dependent transcription" by Arkasubhra Ghosh[1], Gaye Saginc[2], Shi Chi Leow[1], Ekta Khattar[1], Eun Myong Shin[1], Ting Dong Yan[3], Marc Wong[1], Zhizhuo Zhang[4], Guoliang Li[5], Wing-Kin Sung[4,5], Jianbiao Zhou[6], Wee Joo Chng[6], Shang Li[3], Edison Liu[2] and Vinay Tergaonkar[1,7].
[1] Laboratory of NF-kB Signaling, IMCB, Proteos, 138673, Singapore
[2] Cancer Biology and Pharmacology, Genome Institute of Singapore, 138672, Singapore
[3] Program in Cancer and Stem Cell Biology, Duke-NUS Graduate Medical School, 169857, Singapore
[4] School of Computing, National University of Singapore, 119077, Singapore
[5] Computational and Systems Biology, Genome Institute of Singapore, 138672, Singapore
[6] Cancer Science Institute of Singapore, 119074, Singapore
[7] Correspondence should be addressed to: Vinay Tergaonkar (

About A*STAR

The Agency for Science, Technology and Research (A*STAR) is the lead agency for fostering world-class scientific research and talent for a vibrant knowledge-based and innovation-driven Singapore. A*STAR oversees 14 biomedical sciences and physical sciences and engineering research institutes, and six consortia & centres, located in Biopolis and Fusionopolis as well as their immediate vicinity. A*STAR supports Singapore's key economic clusters by providing intellectual, human and industrial capital to its partners in industry. It also supports extramural research in the universities, and with other local and international partners. For more information about A*STAR, please visit .

Source: A*STAR


Vithya Selvam (Ms)
Senior Officer, Corporate Communications
Agency for Science, Technology and Research
Tel: +65 6826 6291

Copyright 2012 ACN Newswire. All rights reserved.

About ACN Newswire
Copyright 2008 ACN Newswire. All rights reserved. Republication or redistribution of ACN Newswire content is expressly prohibited without the prior written consent of ACN Newswire. ACN Newswire shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

Latest Cloud Developer Stories
In today's enterprise, digital transformation represents organizational change even more so than technology change, as customer preferences and behavior drive end-to-end transformation across lines of business as well as IT. To capitalize on the ubiquitous disruption driving this...
The Internet of Things is clearly many things: data collection and analytics, wearables, Smart Grids and Smart Cities, the Industrial Internet, and more. Cool platforms like Arduino, Raspberry Pi, Intel's Galileo and Edison, and a diverse world of sensors are making the IoT a gre...
With all the incredible momentum behind the Internet of Things (IoT) industry, it is easy to forget that not a single CEO wakes up and wonders if “my IoT is broken.” What they wonder is if they are making the right decisions to do all they can to increase revenue, decrease costs,...
I recently attended and was a speaker at the 4th International Internet of @ThingsExpo at the Santa Clara Convention Center. I also had the opportunity to attend this event last year and I wrote a blog from that show talking about how the “Enterprise Impact of IoT” was a key them...
Apps and devices shouldn't stop working when there's limited or no network connectivity. Learn how to bring data stored in a cloud database to the edge of the network (and back again) whenever an Internet connection is available. In his session at 17th Cloud Expo, Ben Perlmutte...
Subscribe to the World's Most Powerful Newsletters
Subscribe to Our Rss Feeds & Get Your SYS-CON News Live!
Click to Add our RSS Feeds to the Service of Your Choice:
Google Reader or Homepage Add to My Yahoo! Subscribe with Bloglines Subscribe in NewsGator Online
myFeedster Add to My AOL Subscribe in Rojo Add 'Hugg' to Newsburst from CNET Kinja Digest View Additional SYS-CON Feeds
Publish Your Article! Please send it to editorial(at)!

Advertise on this site! Contact advertising(at)! 201 802-3021

SYS-CON Featured Whitepapers